North America Epigenetics Diagnostic Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 1,823.57 Million |
 Taille du marché (année de prévision) |
USD 5,810.57 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché du diagnostic épigénétique en Amérique du Nord, par produit ( réactifs , kits, instruments et consommables, outils et enzymes bioinformatiques), technologie (méthylation de l'ADN, méthylation des histones, structures de chromatine, acétylation des histones, modification des grands ARN non codants et des microARN), type de thérapie (inhibiteurs de l'histone désacétylase (HDAC), inhibiteurs de l'ADN méthyltransférase (DNMT) et autres), application ( oncologie , maladies cardiovasculaires, maladies métaboliques , immunologie, maladies inflammatoires, maladies infectieuses et autres), utilisateur final (instituts universitaires et de recherche, sociétés pharmaceutiques et biotechnologiques , organismes de recherche sous contrat (CRO) et autres), canal de distribution (appel d'offres direct et ventes au détail), pays (États-Unis, Canada, Mexique), tendances et prévisions de l'industrie jusqu'en 2028.
Analyse et perspectives du marché : marché nord-américain du diagnostic épigénétique
Le marché nord-américain du diagnostic épigénétique devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 16,0 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 5 810,57 millions USD d'ici 2028 contre 1 823,57 millions USD en 2020. La forte prévalence des troubles chroniques et le développement technologique seront probablement les principaux moteurs qui propulseront la demande du marché au cours de la période de prévision.
Le diagnostic épigénétique est l'étude de la génétique, des variations des traits cellulaires et physiques et de la biologie du développement causées par l'environnement externe. Cela affecte à son tour les gènes et la capacité cellulaire à lire les gènes sans être affecté par les changements de génotype. Les changements épigénétiques entraînent des changements dans le phénotype de l'organisme plutôt que dans le génotype, la séquence d'ADN et d'ARN sous-jacente restant inchangée. Les changements épigénétiques sont essentiels au développement car ils sont dynamiques et changent en fonction de l'environnement.
L'expression génétique des organismes est influencée par l'épigénétique, ce qui en fait le domaine le plus crucial de la biologie moléculaire et de la génétique du développement. Des organisations telles que le National Center Institute, le National Institute of Health et l'International Human Epigenome Consortium financent et soutiennent les activités de recherche et développement liées au domaine de l'épigénétique. L'épigénétique est également utilisée pour traiter diverses maladies chroniques telles que le cancer, les maladies métaboliques et autres.
The North America epigenetics diagnostic market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
North America Epigenetics Diagnostic Market Scope and Market Size
North America epigenetics diagnostic market is categorized into six notable segments which are based on product, technology, type of therapy, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the North America epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes. In 2021, reagents segment is expected to dominate the market as reagents are used in a variety of fields including research, diagnosis, bioscience, and education.
- On the basis of technology, the North America epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification. In 2021, DNA methylation segment is expected to dominate the market as the DNA methylation technology is being used in a variety of epigenetics diagnosis.
- On the basis of type of therapy, the North America epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others. In 2021, histone deacetylase (HDAC) inhibitors segment is expected to dominate the market as it plays a major role in biological processes and regulate gene expression.
- On the basis of application, the North America epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others. In 2021, oncology segment is expected to dominate the market due to the increasing use of epigenetics for cancer diagnosis.
- On the basis of end user, the North America epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others. In 2021, academic and research institutes segment is expected to dominate the market as various research institutes are performing research on the efficacy of epigenetics testing.
- On the basis of distribution channel, the North America epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market due to escalation in marketing activities and improved customer services in North American region.
North America Epigenetics Diagnostic Market Country Level Analysis
North America epigenetics diagnostic market is analysed, and market size information is provided by country, product, technology, type of therapy, application, end user, and distribution channel.
The countries covered in the North America epigenetics diagnostic market report are U.S., Canada and Mexico.
The U.S. is expected to grow in North America epigenetics diagnostic market, due to the increasing demand for epigenetics diagnosis because of high prevalence of chronic diseases and increasing healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the North America Epigenetics Diagnostic Market
North America epigenetics diagnostic market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the epigenetics diagnostic market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and North America Epigenetics Diagnostic Market Share Analysis
North America epigenetics diagnostic market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to epigenetics diagnostic market.
Certaines des principales entreprises fournissant des diagnostics épigénétiques sont Zymo Research Corporation, PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Mnemo, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, New England Biolabs, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., Epizyme, Inc., GlaxoSmithKline plc., Eclipse BioInnovations, MDxHealth, Abcam plc, Salarius Pharmaceuticals, Inc., Datar Cancer Genetics et Bluestar Genomics Inc., entre autres. Les analystes de DBMR comprennent les atouts concurrentiels et fournissent une analyse concurrentielle pour chaque concurrent séparément.
Les initiatives stratégiques des acteurs du marché et les nouvelles avancées technologiques en matière de diagnostic épigénétique comblent le fossé en matière de diversité des traitements.
Par exemple,
- En mai 2021, Abcam Plc. a annoncé l'expansion de sa présence en Chine avec l'ouverture de nouvelles installations sur mesure à Hangzhou et Shanghai. Cette expansion devrait accélérer la croissance des revenus de l'entreprise.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché de l’entreprise sur le marché du diagnostic épigénétique, ce qui offre également l’avantage à l’organisation d’améliorer son offre pour le marché du diagnostic épigénétique.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 REGULATIONS: NORTH AMERICA EPIGENETICS DIAGNOSITC MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CANCER
6.1.2 INCREASE IN NORTH AMERICA GERIATRIC POPULATION
6.1.3 RISE IN RESEARCH & DEVELOPMENT (R&D) ACTIVITIES IN THE FIELD OF EPIGENETICS
6.1.4 PRESENCE OF ADVANCED TECHNOLOGIES TO IMPROVE DIAGNOSTIC EFFICIENCY
6.1.5 IMPROVING HEALTHCARE FACILITIES
6.2 RESTRAINTS
6.2.1 INADEQUACY IN IDENTIFICATION AND VALIDATION OF BIOMARKERS
6.2.2 HIGH COST OF EPIGENETICS DIAGNOSTIC EQUIPMENT
6.3 OPPORTUNITIES
6.3.1 WIDE RANGE OF APPLICATION
6.3.2 PROMOTER METHYLATION IN DIFFERENT TYPES OF CANCER
6.3.3 EMERGING MARKETS
6.3.4 INCREASING HEALTHCARE EXPENDITURE
6.3.5 RISING PER CAPITA INCOME
6.4 CHALLENGES
6.4.1 ESCALATING PRODUCT RECALL
6.4.2 SHORTAGE OF SKILLED PERSONNEL
6.4.3 EMERGENCE OF COVID-19
6.4.4 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID 19
7.5 CONCLUSION:
8 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 REAGENTS
8.2.1 ANTIBODIES
8.2.2 BUFFERS
8.2.3 HISTONES
8.2.4 MAGNETIC BEADS
8.2.5 PRIMERS
8.2.6 OTHERS
8.3 KITS
8.3.1 CHIP SEQUENCING KIT
8.3.2 WHOLE GENOMIC AMPLIFICATION KIT
8.3.3 BISULFITE CONVERSION KIT
8.3.4 5-HMC & 5-MC ANALYSIS KITS
8.3.5 RNA SEQUENCING KIT
8.3.6 OTHERS
8.4 INSTRUMENTS & CONSUMABLES
8.4.1 NEXT-GENERATION SEQUENCERS
8.4.2 QPCR
8.4.3 MASS SPECTROMETERS
8.4.4 SONICATORS
8.4.5 OTHERS
8.5 BIOINFORMATICS TOOLS
8.6 ENZYMES
8.6.1 DNA-MODIFYING ENZYMES
8.6.2 PROTEIN-MODIFYING ENZYMES
8.6.3 RNA-MODIFYING ENZYMES
8.6.4 OTHERS
9 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 DNA METHYLATION
9.2.1 REAGENTS
9.2.2 KITS
9.2.3 INSTRUMENTS & CONSUMABLES
9.2.4 ENZYMES
9.3 HISTONE METHYLATION
9.3.1 REAGENTS
9.3.2 KITS
9.3.3 INSTRUMENTS & CONSUMABLES
9.3.4 ENZYMES
9.4 HISTONE ACETYLATION
9.4.1 REAGENTS
9.4.2 KITS
9.4.3 INSTRUMENTS & CONSUMABLES
9.4.4 ENZYMES
9.5 LARGE NON-CODING RNA
9.5.1 REAGENTS
9.5.2 KITS
9.5.3 INSTRUMENTS & CONSUMABLES
9.5.4 ENZYMES
9.6 MICRORNA MODIFICATION
9.6.1 REAGENTS
9.6.2 KITS
9.6.3 INSTRUMENTS & CONSUMABLES
9.6.4 ENZYMES
9.7 CHROMATIN STRUCTURES
9.7.1 REAGENTS
9.7.2 KITS
9.7.3 INSTRUMENTS & CONSUMABLES
9.7.4 ENZYMES
10 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY
10.1 OVERVIEW
10.2 HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 DNA METHYLTRANSFERASE (DNMT) INHIBITORS
10.4 OTHERS
11 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.2.1 SOLID TUMORS
11.2.2 LIQUID TUMORS
11.3 CARDIOVASCULAR DISEASES
11.4 METABOLIC DISEASES
11.4.1 METABOLIC SYNDROME
11.4.2 TYPE 2 DIABETES (T2D)
11.4.3 OTHERS
11.5 IMMUNOLOGY
11.6 INFLAMMATORY DISEASES
11.7 INFECTIOUS DISEASES
11.8 OTHERS
12 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 ACADEMIC AND RESEARCH INSTITUTES
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
12.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
12.5 OTHERS
13 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ILLUMINA, INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 MERCK KGAA
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 BIO-RAD LABORATORIES, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN-LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 RECENT FINANCIALS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 AGILENT TECHNOLOGIES, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PERKINELMER INC
17.7.1 COMPANY SNAPSHOT
17.7.2 RECENT FINANCIALS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 QIAGEN
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 ABCAM PLC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ACTIVEMOTIF
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BLUESTAR GENOMICS INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CAMBRIDGE EPIGENETIX (CEGX)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 DATAR CANCER GENETICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 DIAGENODE
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ECLIPSE BIOINNOVATIONS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENZO LIFE SCIENCES, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 EPICYPHER
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 EPIGENOMICS AG
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 EPIGENTEK GROUP INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 EPIZYME, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 GLAXOSMITHKLINE PLC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MDXHEALTH
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 MNEMO
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENT
17.24 NEW ENGLAND BIOLABS
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17.25.1 COMPANY SNAPSHOT
17.25.2 RECENT FINANCIALS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENTS
17.26 PROMEGA CORPORATION
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 REACTION BIOLOGY
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SALARIUS PHARMACEUTICALS, INC.
17.28.1 COMPANY SNAPSHOT
17.28.2 RECENT FINANCIALS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 ZYMO RESEARCH CORPORATION
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 HEALTH CARE FACILITIES
TABLE 2 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)
TABLE 3 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 NORTH AMERICA KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA BIOINFORMATICS TOOLS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA HISTONE DEACETYLASE (HDAC) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA DNA METHYLTRANSFERASE (DNMT) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA CARDIOVASCULAR DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA IMMUNOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA INFLAMMATORY DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA INFECTIOUS DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS (CROS) IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA DIRECT TENDER IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA RETAIL SALES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 NORTH AMERICA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 U.S. EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 U.S. REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 69 U.S. KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 70 U.S. INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 71 U.S. ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 72 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 U.S. DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 U.S. HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 U.S. HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 U.S. LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 77 U.S. MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 78 U.S. CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 79 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 80 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 U.S. ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 U.S. METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 U.S. EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 CANADA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 CANADA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 CANADA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 CANADA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 89 CANADA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 90 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 CANADA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 92 CANADA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 93 CANADA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 CANADA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 CANADA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 CANADA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 98 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 99 CANADA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 100 CANADA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 CANADA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 103 MEXICO EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 104 MEXICO REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 105 MEXICO KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 MEXICO INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 107 MEXICO ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 108 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 109 MEXICO DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 110 MEXICO HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 111 MEXICO HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 112 MEXICO LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 113 MEXICO MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 114 MEXICO CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 115 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 116 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 MEXICO ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 118 MEXICO METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 119 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 120 MEXICO EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET
FIGURE 15 EPIGENETIC REGULATION IN CANCER
FIGURE 16 PREVALENCE OF CANCER WORLDWIDE
FIGURE 17 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES WORLDWIDE
FIGURE 18 NORTH AMERICA AGING POPULATION (IN MILLIONS)
FIGURE 19 GERIATRIC POPULATION WORLWIDE
FIGURE 20 NCI FUNDING FOR CANCER RESEARCH
FIGURE 21 EPIGENETIC IVD TESTS
FIGURE 22 THREE NEXT GENERATION SEQUENCING PLATFORMS
FIGURE 23 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2020
FIGURE 24 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 25 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 26 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 27 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2020
FIGURE 28 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 29 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 30 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2020
FIGURE 32 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2021-2028 (USD MILLION)
FIGURE 33 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, CAGR (2021-2028)
FIGURE 34 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, LIFELINE CURVE
FIGURE 35 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2020
FIGURE 36 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 37 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 38 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 39 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2020
FIGURE 40 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 41 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, CAGR (2021-2028)
FIGURE 42 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 45 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 46 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: SNAPSHOT (2020)
FIGURE 48 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020)
FIGURE 49 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT (2021-2028)
FIGURE 52 NORTH AMERICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
